Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
144 stopped studies mapped to Exocrine Pancreas Carcinoma and descendants · 93% state a reason
Over the 144 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced…(LAPC-BC-819) | Phase 2 | terminated | Aug 10, 2011 | Anchiano Therapeutics Israel Ltd. | Due to Sponsor's decision, only 12 patients were randomized \& completed study. | Sponsor / business decision |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and… | Phase 2 | withdrawn | Oct 17, 2019 | Indiana University | Study is being abandoned. | Other (stated, no rule matched) |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic… | Early Phase 1 | terminated | Mar 29, 2018 | PH Research, S.L. | Stopped Enrollment | Enrollment / accrual |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With… | Phase 1 | terminated | Mar 14, 2016 | The Cooper Health System | Closed after being on administrative hold | Other (stated, no rule matched) |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance… | Phase 1 | terminated | Dec 3, 2012 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic…(PANCREADOGREL) | Phase 3 | terminated | Mar 31, 2015 | Assistance Publique - Hôpitaux de Paris | recruitment problem | Enrollment / accrual |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or… | Phase 1 / Phase 2 | withdrawn | Dec 19, 2018 | Alan Katz | CCX872-B will not be available in sufficient quantity to conduct the study. | Other (stated, no rule matched) |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | Phase 2 | terminated | Apr 28, 2014 | CCTU- Cancer Theme | Poor accrual | Enrollment / accrual |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients… | Phase 2 | terminated | Apr 13, 2016 | Eben Rosenthal | Logistics | Other (stated, no rule matched) |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin +… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2018 | Hitendra Patel | FDA indicated the same study could not be conducted under multiple INDs | Other (stated, no rule matched) |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | Phase 2 | withdrawn | Feb 14, 2018 | M.D. Anderson Cancer Center | Incyte (supporter of the study) is no longer going to support the study. | Other (stated, no rule matched) |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and… | Phase 1 / Phase 2 | withdrawn | Apr 9, 2019 | Medical College of Wisconsin | Request to close per funding sponsor. Site not moving forward with trial. | Funding |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot… | Phase 1 | terminated | May 25, 2016 | University of Chicago | Closed early due to poor accrual. | Enrollment / accrual |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | Phase 2 | terminated | Jan 4, 2013 | Beth Israel Medical Center | not stated | Not stated |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line… | Phase 2 | terminated | Dec 2, 2011 | University Health Network, Toronto | not stated | Not stated |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally… | Phase 4 | withdrawn | Oct 7, 2015 | Yonsei University | Investigator decided to stop the study because it was difficult to proceed with the study. | Investigator |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and… | Phase 2 | terminated | Aug 13, 2013 | Radiation Therapy Oncology Group | Trial would not be completed in a reasonable timeframe per CTEP guidelines | Other (stated, no rule matched) |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | Phase 2 | terminated | Jan 26, 2015 | Case Comprehensive Cancer Center | Competing studies | Other (stated, no rule matched) |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | Phase 2 | terminated | May 24, 2011 | University of Oklahoma | The principal investigator terminated the study due to inactivity and low enrollment | Investigator |
| NCT02496832 | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With… | N/A | withdrawn | Jul 14, 2015 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01911416 | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog… | N/A | withdrawn | Jul 30, 2013 | University of Utah | No accrual | Enrollment / accrual |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Oct 14, 2015 | Roswell Park Cancer Institute | drug supply issues | Drug supply |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | Early Phase 1 | terminated | Oct 14, 2013 | University of Virginia | From preliminary imaging data, the study was stopped due to futility. | Efficacy / futility |
| NCT00598091 | A Phase I/Expansion Study of Dasatinib(Gem/Dsat) | Phase 1 | terminated | Jan 18, 2008 | Duke University | Low accrual, unable to meet endpoint in timely manner | Enrollment / accrual |
| NCT01419002 | Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in…(Net-Pac) | Phase 3 | terminated | Aug 17, 2011 | CHIR-Net | lack of recruitment | Enrollment / accrual |
| NCT01050283 | A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With… | Phase 1 | terminated | Jan 15, 2010 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are… | Phase 2 | withdrawn | Nov 15, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01227018 | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer | Phase 2 | terminated | Oct 22, 2010 | Vanderbilt-Ingram Cancer Center | interim analysis found the study drug to be ineffective | Efficacy / futility |
| NCT01741597 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With… | Phase 1 | withdrawn | Dec 5, 2012 | City of Hope Medical Center | PI chose to close the study | Other (stated, no rule matched) |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 3, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01096732 | Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative…(HIPPoS) | Phase 2 | terminated | Mar 31, 2010 | Lisa Bax | Slow recruitment | Enrollment / accrual |
| NCT01192763 | RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer | Phase 1 | terminated | Sep 1, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01830322 | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic… | Phase 2 | withdrawn | Apr 12, 2013 | Cornerstone Pharmaceuticals | not stated | Not stated |
| NCT01401387 | Pancreatic Enzyme Suppletion in Pancreatic Cancer(EPC) | Phase 4 | withdrawn | Jul 25, 2011 | Foundation for Liver Research | study never started | Other (stated, no rule matched) |
| NCT00593008 | Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic… | Phase 1 | terminated | Jan 14, 2008 | Massachusetts General Hospital | not stated | Not stated |
| NCT00307723 | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation… | Phase 1 / Phase 2 | terminated | Mar 28, 2006 | Massachusetts General Hospital | poor accrual | Enrollment / accrual |
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced… | Phase 1 | terminated | Jan 3, 2008 | Anza Therapeutics, Inc. | not stated | Not stated |
| NCT00637364 | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain(HIFU Pancreas) | Phase 1 / Phase 2 | suspended | Mar 18, 2008 | CMED HIFU Development Corporation | Sponsor is not proceeding with USA human trial at this time | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 1, 2019source: clinicaltrials